Alternate-Day Statin Therapy for the Treatment of Hyperlipidemia

Abstract

Spanish

Objective:

To evaluate the safety, efficacy, and cost of alternate-day statin therapy in the treatment of hyperlipidemia.

Data Sources:

Systematic searches were conducted for primary literature sources involving alternative statin regimens using PubMed, EMBASE, Google Scholar, and International Pharmaceutical Abstracts (January 1966-March 2010). Articles selected were limited to those published in the English language. Reference citations from relevant publications identified were also reviewed.

Study Selection and Data Extraction:

All English-language articles identified were reviewed and 17 trials (14 prospective and 3 retrospective) involving alternate-day statin dosing were included. Studies involving alternative statin dosing regimens other than alternating days were excluded from this review.

Data Synthesis:

Daily administration of statins is the standard of therapy used to reduce low-density lipoprotein cholesterol (LDL-C) levels as well as atherosclerosis that may lead to coronary events. Through LDL-C lowering and pleiotrope effects, statins decrease cardiovascular morbidity and mortality. Unfortunately, due to cost and adverse effects of statins, some patients are nonadherent to statin therapy. Several small studies have found alternate-day statin therapy to be as effective at reducing LDL-C as daily administration, while also lowering the incidence of adverse reactions and potentially lowering cost.

Conclusions:

Alternate-day statin therapy may decrease cost and therapy-limiting adverse reactions while potentially increasing regimen adherence and positively affecting the lipid panel. Further research is needed to determine whether this alternative regimen produces similar cardiovascular outcomes as those with daily statin therapy,

Keywords

adherence alternative dosing regimen HMG-CoA reductase inhibitors hyperlipidemia statins

Get full access to this article

View all access options for this article.

References

American Heart Association. Heart disease and stroke statistics. 2010 update. http://www.americanheart.org/downloadable/heart/1265665152970DS-3241%20HeartStrokeUpdate_2010.pdf (accessed 15 Mar 2010).

Talbert

. Safety issues with statin therapy. J Am Pharm Assoc 2006; 46:479–90. DOI 10.1331/154434506778073637

National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143–421.

Grundy

, Cleeman

, Merz

CNB

. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 13:227–39. DOI 10.1161/01.CIR.0000133317.49796.0E

Ginsberg

. REVIEW: efficacy and mechanisms of action of statins in the treatment of diabetic dsylipidemia. J Clin Endocrinol Metab 2006; 91:383–92. DOI 10.1210/jc.2005–2084

Liao

, Laufs

. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45:89–118. DOI 10.1146/annurev.pharmtox.45.120403.095748

Prescribing information. Mevacor (lovastatin). Whitehouse Station, NJ: Merck & Co., Inc., October 2009.

Prescribing information. Zocor (simvastatin). Whitehouse Station, NJ: Merck & Co., Inc., March 2010.

Prescribing information. Lescol (fluvastatin). East Hanover, NJ: Novartis Pharmaceuticals Co., October 2006.

10.

Prescribing information. Livalo (pravastatin). Montgomery, AL: Kowa Pharmaceuticals America, Inc., October 2009

11.

Prescribing information. Crestor (rosuvastatin). Wilmington, DE: Astra Zeneca Pharmaceuticals, February 2010.

12.

Prescribing information. Lipitor (atorvastatin). New York, NY: Pfizer Inc., June 2009.

13.

Prescribing information. Pravachol (pravastatin). Princeton, NJ: Bristol-Myers Squibb Co., March 2010.

14.

Walmart discount prescription plan. http;//i.walmartimages.com/i/if/hmp/fusion/customer_list.pdf (accessed 19 Mar 2010).

15.

Walgreens prescription savings club, https://webapp.walgreens.com/MYWCARDWeb/pdf/Value-PricedGenericsList.pdf. (accessed 19 Mar 2010).

16.

Target discount prescription plan, http://www.rxassist.org/providers/documents/TargetGenericsProgramDrugList.pdf (accessed 19 Mar 2010).

17.

CVS health savings pass. http://www.cvs.com/CVSApp/rmages/promnotions/landingpages/rx/rx08037_health_sav_pass/health_savings_pass_medicationlist.pdf (accessed 19 Mar 2010).

18.

K-Mart discount prescription plan. http://www.kmart.com/ue/home/kmart_pharmacy_15_dollar_list_jan2010.pdf (accessed 19 Mar 2010).

19.

Rite Aid discount prescription plan. http://www.riteaid.com/www.riteaid.com/w-content/images/pharmacy/20100203_EVRA947_RXSavings_Directory.pdf (accessed 19 Mar 2010).

20.

Mitka

. Expanding statin use to help more at-risk patients is causing financial heartburn. JAMA 2003; 290:2243–5. DOI 10.1001/jama.290.17.2243

21.

Joy

, Hegele

. Narrative review: statin related myopathy. Ann Intern Med 2009; 150:858–68.

22.

Metz

, Lucas

. Alternate-day dosing of HMG-CoA reductase inhibitors for cholesterol reduction. Ann Pharmacother 2001;35:496–500. DOI 10.1345/aph.10164

23.

Rindone

, Achacoso

, Bledsoe

. Effect of lovastatin administered every other day on serum low-density lipoprotein cholesterol >160 mg/dL. Am J Cardiol 1995; 76:312–3. DOI 10.1016/S0002-9149(99)80089–7

24.

Dennis

, Britton

, Sirmans

, Letassy

, Freeman

. The use of alternate-day lovastatin in hyperchoiestemic men. Ann Pharmacother 1997; 31:708–12.

25.

Rindone

, Hiller

, Arriola

. A comparison of fluvastatin 40 mg every other day versus 20 mg every day in patients with hypercholesterolemia. Pharmacotherapy 1998; 18:836–9.

26.

Graham

, Lindsey

, Kennedy

. Maintenance of low-density lipoprotein goal with step-down pravastatin therapy. Pharmacotherapy 2002; 22:21–6. DOI 10.1592/phco22.1.21.33506

27.

Kayikcioglu

, Ozerkan

, Soydan

. Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia. Am J Cardiol 1999; 83:1135–7. DOI 10.1016/S0002–9149(99)00030–2

28.

Copher

, Stewart

. Daily dosing versus alternate-day dosing of simvastatin in patients with hypercholesterolemia. Pharmacotherapy 2002;22:1110–6. DOI 10.1592/phco.22.13.111033518

29.

Matalka

, Ravnan

, Deedwania

. Is alternative daily dose of atorvastatin effective in treating patients with hyperlipidemia? The alternate day versus daily dosing of atorvastatin study (ADDAS). Am Heart J 2002; 144:674–7. DOI 10.1067/mhj.2002.124399

30.

Jafari

, Ebrahimi

, Ahmadi-Kashani

, Balian

, Bahir

. Efficacy of alternate-day dosing versus daily dosing of atorvastatin. J Cardiovasc Pharmacol Ther 2003; 8:123–6. DOI 10.1177/107424840300800205

31.

Piamsomboon

, Laothavorn

, Saguanwong

. Efficacy and safety of atorvastatin 10 mg every other day in hypercholesterolemia. J Med Assoc Thai 2002; 85:297–300.

32.

Ferrer-Garcia

, Perez-Silvesre

, Martinez-Mir

, Herrera-Ballester

. Alternate-day dosing of atorvastatin: effects in treating type 2 diabetic patients with dyslipidemia. Acta Diabetol 2006; 43:75–8. DOI 10.1007/S00592–006–0216–4

33.

Aghasadeghi

, Zare

. Efficacy of alternate day dosing of atorvastatin. Cent Eur J Med 2007; 3:163–6.

34.

Keles

, Bayram

, Kayhan

. The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg of atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels. Anadolu Kardiyol Derg 2008; 8:407–12.

35.

Wongwiwatthananukit

, Sansanayudh

, Dhummauppakorn

, Kitiyadisai

. Efficacy and safety of rosuvastatin every other day compared with once daily patients with hypercholesterolemia. Ann Pharmacother 2006; 40:1917–23. DOI 10.1345/aph.1H124

36.

Backes

, Venero

, Gibson

, Ruisinger

, Howard

, Thompson

, Moriarty

. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother 2008; 42:341–6. DOI 10.1345/aph.1K604

37.

Jewkes

, Jones

. Alternate day low dose rosuvastatin for the treatment of patients intolerant of conventional statin dosing regimens. 77th Congress of the European Atherosclerosis Society; 2008 April 26-29; Istanbul, Turkey. Atheroscler Suppl 2008; 9:229. DOI 10.1016/S1567–5688(08)70913–9

38.

Dulay

, LaHaye

, Lahey

, Day

. Efficacy of alternate day versus daily dosing of rosuvastatin. Can J Cardiol 2009; 25:e28–31.

39.

Juszczyk

, Seip

, Thompson

. Decreasing LDL cholesterol and medication cost with every-other-day statin therapy. Prev Cardiol 2005; 197–9. DOI 10.1111/j.0197–3118. 2005.04404.x